Shield Therapeutics PLC (LON:STX) has announced the appointment of Hans Peter Hasler as the company’s non-executive chairman with effect from its annual general meeting (AGM) to be held on June 18, 2020.
The commercial stage, pharmaceutical company, with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol) announced on May 21 that its current chairman, James Karis would not seek re-election and would be stepping down at the AGM.
READ: Shield Therapeutics CEO says finding a US partner for lead drug is "top priority" for 2020
It noted that Hasler joined Shield's board of directors in July 2018 and has served as chairman of the Nomination Committee and a member of the Audit Committee.
He has prior executive experience including as chief operating officer at both Elan Corporation and Biogen Inc. as well as chief marketing officer of Wyeth Pharmaceuticals, and is currently non-executive chairman of HBM Healthcare Investments AG, Zug/Switzerland and a non-executive director of Minerva Neuroscience Inc., the group added.
In a statement, Tim Watts, CEO of Shield Therapeutics, commented: "I am very pleased to see Hans Peter appointed as our Chairman. I have worked increasingly closely with Hans Peter over the last two years and value his experience and insights and the support he has given me personally."
Hasler added: "I am delighted to have been appointed as Chairman of Shield at a critical time for the Group. Feraccru/ Accrufer is an excellent product with enormous potential and I look forward to continuing to help the Group find ways of making it available to the widest possible number of patients and to translating that into value for shareholders. I also look forward to working with the rest of the Board and the management team in these endeavours."